| Original language | English |
|---|---|
| Article number | 116603 |
| Journal | Journal of the Neurological Sciences |
| Volume | 409 |
| DOIs | |
| Publication status | Published - Feb 15 2020 |
Keywords
- Anti-CD20
- Late onset absolute neutropenia
- Monoclonal antibody treatment
- Multiple sclerosis
- Ocrelizumab
- Treatment naïve
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis : A case report and review of the literature. / Zanetta, Chiara; Robotti, Micaela; Nozzolillo, Agostino et al.
In: Journal of the Neurological Sciences, Vol. 409, 116603, 15.02.2020.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis
T2 - A case report and review of the literature
AU - Zanetta, Chiara
AU - Robotti, Micaela
AU - Nozzolillo, Agostino
AU - Sangalli, Francesca
AU - Liberatore, Giuseppe
AU - Nobile-Orazio, Eduardo
AU - Filippi, Massimo
AU - Moiola, Lucia
N1 - Funding Information: Dr. Zanetta, Dr. Nozzolillo and Dr. Sangalli have nothing to disclose. Dr. Robotti received fundings from Novartis. Dr. Liberatore reported travel grants to attend scientific meetings from CSL Behring and Kedrion. Prof. Eduardo Nobile-Orazio reported personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, LFB, France, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. Dr. Moiola received compensation for speaking activities, and/or consulting servicesfrom Merck, Biogen, Novartis, Roche, Sanofi, and TEVA. Prof. Filippi is Editor-in-Chief of the Journal of Neurology, received compensation for consulting services and/or speaking activities from Biogen Idec , Merck-Serono, Novartis, Teva Pharmaceutical Industries ; and receives research support from Biogen Idec , Merck-Serono, Novartis, Teva Pharmaceutical Industries , Roche, Italian Ministry of Health , Fondazione Italiana Sclerosi Multipla , and ARiSLA (Fondazione Italiana di Ricerca per la SLA) . Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2020/2/15
Y1 - 2020/2/15
KW - Anti-CD20
KW - Late onset absolute neutropenia
KW - Monoclonal antibody treatment
KW - Multiple sclerosis
KW - Ocrelizumab
KW - Treatment naïve
UR - http://www.scopus.com/inward/record.url?scp=85075874946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075874946&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2019.116603
DO - 10.1016/j.jns.2019.116603
M3 - Letter
C2 - 31811986
AN - SCOPUS:85075874946
VL - 409
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
M1 - 116603
ER -